Camrelizumab combined with apatinib in patients with first-line platinum-resistant or PD-1 inhibitor resistant recurrent/metastatic nasopharyngeal carcinoma: a single-arm, phase 2 trial - Yuan, Li; Jia, Guo-Dong; Lv, Xiao-Fei; Xie, Si-Yi; Guo, Shan-Shan; Lin, Da-Feng; Liu, Li-Ting; Luo, Dong-Hua; Li, Yi-Fu; Deng, Shen-Wen; Guo, Ling; Zeng, Mu-Sheng; et al. (Nature communications, 2023)
Keywords: 13/51; 631/67/1536; 631/67/2328; 631/67/580; Angiogenesis; Antiangiogenics; Biomarkers; Cancer; Disease control; Effectiveness; Gene expression; Genes; Humanities and Social Sciences; Immune checkpoint inhibitors; Immunotherapy; Inhibitors; Lymphocytes B; Metastases; Metastasis; multidisciplinary; Nasopharyngeal carcinoma; PD-1 protein; PD-L1 protein; Platinum; Safety; Science; Science (multidisciplinary); Solid tumors; Survival; Throat cancer; Tumors; Vascular endothelial growth factor